151 related articles for article (PubMed ID: 27593417)
1. Comparison of efficacy and local tolerability of estradiol metered-dose transdermal spray to estradiol patch in a network meta-analysis.
Kovács G; Zelei T; Vokó Z
Climacteric; 2016 Oct; 19(5):488-95. PubMed ID: 27593417
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause.
Notelovitz M; Cassel D; Hille D; Furst KW; Dain MP; VandePol C; Skarinsky D
Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):7-12. PubMed ID: 10649149
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a new 7-day transdermal sequential estradiol/levonorgestrel patch in women.
von Holst T; Salbach B
Maturitas; 2002 Mar; 41(3):231-42. PubMed ID: 11886769
[TBL] [Abstract][Full Text] [Related]
4. The use of estradiol metered-dose transdermal spray in clinical practice.
Fait T; Fialova A; Pastor Z
Climacteric; 2018 Dec; 21(6):549-553. PubMed ID: 30296172
[TBL] [Abstract][Full Text] [Related]
5. Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial.
Buster JE; Koltun WD; Pascual ML; Day WW; Peterson C
Obstet Gynecol; 2008 Jun; 111(6):1343-51. PubMed ID: 18515518
[TBL] [Abstract][Full Text] [Related]
6. [Transdermal estrogen spray in therapy of postmenopausal syndrome].
Fait T
Ceska Gynekol; 2016 Jan; 81(1):77-80. PubMed ID: 26982070
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study.
Pornel B; Genazzani AR; Costes D; Dain MP; Lelann L; Vandepol C
Maturitas; 1995 Nov; 22(3):207-18. PubMed ID: 8746878
[TBL] [Abstract][Full Text] [Related]
8. Clinical usefulness of a low-dose maintenance therapy with transdermal estradiol gel in Japanese women with estrogen deficiency symptoms.
Mizunuma H
Climacteric; 2011 Oct; 14(5):581-9. PubMed ID: 21848497
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of estradiol transdermal preparations for the treatment of vasomotor symptoms in postmenopausal women: an indirect comparison meta-analysis.
Derzko C; Sergerie M; Siliman G; Alberton M; Thorlund K
Menopause; 2016 Mar; 23(3):294-303. PubMed ID: 26382309
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, open-label study to evaluate satisfaction and menopausal quality of life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and symptoms.
Adler G; Young D; Galant R; Quinn L; Witchger MS; Maki KC
Gynecol Obstet Invest; 2005; 59(4):212-9. PubMed ID: 15753617
[TBL] [Abstract][Full Text] [Related]
11. Comparison of steady state development and reduction of menopausal symptoms after oral or transdermal delivery of 17-β-estradiol in young healthy symptomatic menopausal women.
Rohr UD; Volko CD; Schindler AE
Horm Mol Biol Clin Investig; 2014 Jun; 18(3):123-36. PubMed ID: 25390008
[TBL] [Abstract][Full Text] [Related]
12. A randomized study to compare the effectiveness, tolerability, and acceptability of two different transdermal estradiol replacement therapies. The Transdermal HRT Investigators Group.
Int J Fertil Menopausal Stud; 1993; 38(1):5-11. PubMed ID: 8485612
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Alora estradiol matrix transdermal delivery system with oral conjugated equine estrogen therapy in relieving menopausal symptoms. Alora Study Group.
Good WR; John VA; Ramirez M; Higgins JE
Climacteric; 1999 Mar; 2(1):29-36. PubMed ID: 11915854
[TBL] [Abstract][Full Text] [Related]
14. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
Bachmann GA; Schaefers M; Uddin A; Utian WH
Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of a new 7-day transdermal estradiol patch versus placebo in hysterectomized women with postmenopausal complaints.
von Holst T; Salbach B
Maturitas; 2000 Feb; 34(2):143-53. PubMed ID: 10714909
[TBL] [Abstract][Full Text] [Related]
16. Dose-response efficacy of a new estradiol transdermal matrix patch for 7-day application: a randomized, double-blind, placebo-controlled study. Italian Menopause Research Group.
Rovati LC; Setnikar I; Genazzani AR
Gynecol Endocrinol; 2000 Aug; 14(4):282-91. PubMed ID: 11075300
[TBL] [Abstract][Full Text] [Related]
17. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Rozenberg S; Ylikorkala O; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
[TBL] [Abstract][Full Text] [Related]
18. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies.
Rovati LC; Schmid K; Giacovelli G; Bonn M; Setnikar I; Wolff F; Genazzani AR
Arzneimittelforschung; 1999 Nov; 49(11):933-43. PubMed ID: 10604047
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy.
Gordon SF
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 2):998-1004. PubMed ID: 7573298
[TBL] [Abstract][Full Text] [Related]
20. Low-dose estradiol spray: a novel treatment for vasomotor instability in postmenopausal women.
Buster JE
Womens Health (Lond); 2009 Jan; 5(1):23-8. PubMed ID: 19102636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
